Broad H3K4me3 domains: Maintaining cellular identity and their implication in super-enhancer hijacking – Kent D, Marchetti L, Mikulasova A, Russell LJ, Rico D. Bioessays. 2023 Oct;45(10):e2200239
Molecular characterization and clinical outcome of B-cell precursor acute lymphoblastic leukemia with IG-MYC rearrangement – Bomken S, Enshaei A, Schwalbe EC, Mikulasova A, Dai Y, Zaka M, Fung KTM, Bashton M, Lim H, Jones L, Karataraki N, Winterman E, Ashby C, Attarbaschi A, Bertrand Y, Bradtke J, Buldini B, Burke GAA, Cazzaniga G, Gohring G, De Groot-Kruseman HA, Haferlach C, Nigro LL, Parihar M, Plesa A, Seaford E, Sonneveld E, Strehl S, Van der Velden VHJ, Rand V, Hunger SP, Harrison CJ, Bacon CM, Van Delft FW, Loh ML, Moppett J, Vormoor J, Walker BA, Moorman AV, Russell LJ. Haematologica. 2023 Mar 1;108(3):717-731.
High-resolution simulations of chromatin folding at genomic rearrangements in malignant B cells provide mechanistic insights into proto-oncogene deregulation – Rico, D., D. Kent, N. Karataraki, A. Mikulasova, R. Berlinguer-Palmini, B. A. Walker, B. M. Javierre, L. J. Russell and C. A. Brackley (2022). Genome Res 32(7): 1355-1366.
Epigenomic translocation of H3K4me3 broad domains over oncogenes following hijacking of super-enhancers – Mikulasova, A., D. Kent, M. Trevisan-Herraz, N. Karataraki, K. T. M. Fung, C. Ashby, A. Cieslak, S. Yaccoby, F. van Rhee, M. Zangari, S. Thanendrarajan, C. Schinke, G. J. Morgan, V. Asnafi, S. Spicuglia, C. A. Brackley, A. E. Corcoran, S. Hambleton, B. A. Walker, D. Rico and L. J. Russell (2022). Genome Res 32(7): 1343-1354.
Combination p53 activation and BCL-x(L)/BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia – Bell, H. L., H. J. Blair, S. J. Jepson Gosling, M. Galler, D. Astley, A. V. Moorman, O. Heidenreich, G. J. Veal, F. W. van Delft, J. Lunec and J. A. E. Irving (2024). Leukemia 38(6): 1223-1235.
Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia – Bell, H. L., H. J. Blair, M. Singh, A. V. Moorman, O. Heidenreich, F. W. van Delft, J. Lunec and J. A. E. Irving (2023). Cancer Cell Int 23(1): 202.
Selection of dormant cells during treatment of T-lineage lymphoblastic leukemia and CREB as a therapeutic target – Masic, D., H. Bell, F. W. Van Delft and J. A. E. Irving (2024). Haematologica 109(7): 2316-2320.
Hyperactive CREB subpopulations increase during therapy in pediatric B-lineage acute lymphoblastic leukemia – Masic, D., K. Fee, H. Bell, M. Case, G. Witherington, S. Lansbury, J. Ojeda-Garcia, D. McDonald, C. Schwab, F. W. Van Delft, A. Filby and J. A. E. Irving (2023). Haematologica 108(4): 981-992.
The genomic landscape of teenage and young adult T-cell acute lymphoblastic leukemia – Mansur MB, Furness CL, Nakjang S, Enshaei A, Alpar D, Colman SM, Minto L, Irving J, Poole BV, Noronha EP, Savola S, Iqbal S, Gribben J, Pombo-de-Oliveira MS, Ford TM, Greaves MF, van Delft FW. Cancer Med. 2021 Jul;10(14):4864-4873. doi: 10.1002/cam4.4024. Epub 2021 Jun 2. PMID: 34080325
Phase II-like murine trial identifies synergy between dexamethasone and dasatinib in T-cell acute lymphoblastic leukemia – Shi Y, Beckett MC, Blair HJ, Tirtakusuma R, Nakjang S, Enshaei A, Halsey C, Vormoor J, Heidenreich O, Krippner-Heidenreich A, van Delft FW. Haematologica. 2021 Apr 1;106(4):1056-1066. doi: 10.3324/haematol.2019.241026. PMID: 32139432
Integration of genetics and MRD to define low risk patients with B-cell precursor acute lymphoblastic leukaemia with intermediate MRD levels at the end of induction – Moorman AV, Enshaei A, Murdy D, Joy M, Boer JM, den Boer ML, Pieters R, de Haas V, Horstmann MA, Escherich G, Johansson B, Marquart HV, Schmiegelow K, Hancock J, Moppett J, Heyman M.Leukemia. 2024 Sep;38(9):2023-2026. doi: 10.1038/s41375-024-02329-0. Epub 2024 Jul 5.PMID: 38965371
A robust and validated integrated prognostic index for defining risk groups in adult acute lymphoblastic leukemia: an EWALL collaborative study – Enshaei A, Joy M, Butler E, Kirkwood AA, Messina M, Pavoni C, Morgades M, Harrison CJ, Foà R, Ribera JM, Chiaretti S, Bassan R, Fielding AK, Moorman AV.Blood Adv. 2024 Mar 12;8(5):1155-1166. doi: 10.1182/bloodadvances.2023011661.PMID: 38113467
Integrative genomic analysis of childhood acute lymphoblastic leukaemia lacking a genetic biomarker in the UKALL2003 clinical trial –Schwab C, Cranston RE, Ryan SL, Butler E, Winterman E, Hawking Z, Bashton M, Enshaei A, Russell LJ, Kingsbury Z, Peden JF, Barretta E, Murray J, Gibson J, Hinchliffe AC, Bain R, Vora A, Bentley DR, Ross MT, Moorman AV, Harrison CJ.Leukemia. 2023 Mar;37(3):529-538. doi: 10.1038/s41375-022-01799-4. Epub 2022 Dec 22.PMID: 36550215
Time to Cure for Childhood and Young Adult Acute Lymphoblastic Leukemia Is Independent of Early Risk Factors: Long-Term Follow-Up of the UKALL2003 Trial – Moorman AV, Antony G, Wade R, Butler ER, Enshaei A, Harrison CJ, Moppett J, Hough R, Rowntree C, Hancock J, Goulden N, Samarasinghe S, Vora A.J Clin Oncol. 2022 Dec 20;40(36):4228-4239. doi: 10.1200/JCO.22.00245. Epub 2022 Jun 17.PMID: 35714315
Deconvolution of cancer methylation patterns determines that altered methylation in cancer is dominated by a non-disease associated proliferation signal – H Lalchungnunga, H Atasoy, EC Schwalbe, CM Bacon, G Strathdee. bioRxiv 2024
Epigenome-wide analysis across the development span of pediatric acute lymphoblastic leukemia: backtracking to birth – Ghantous A, Nussle SG, Nassar FJ, Spitz N, Novoloaca A, Krali O, Nickels E, Cahais V, Cuenin C, Roy R, Li S, Caron M, Lam D, Fransquet PD, Casement J, Strathdee G, Pearce MS, Hansen HM, Lee H-H, Lee YS, de Smith AJ, Sinnett D, Haberg SE, McKay JA, Nordlund J, Magnus P, Dwyer T, Saffery R, Wiemels JL, Munthe-Kaas MC, Herceg Z. Molecular Cancer volume 23, Article number: 238 (2024)